Form 8K Adial Pharmaceuticals Inc For: 17 August
- Investing.com
Metrics to compare | ADIL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADILPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −0.4x | −0.3x | |
PEG Ratio | −0.01 | −0.09 | 0.00 | |
Price/Book | −0.2x | 1.2x | 2.6x | |
Price / LTM Sales | - | 2.3x | 2.9x | |
Upside (Analyst Target) | 177.8% | 98.2% | 64.3% | |
Fair Value Upside | Unlock | 27.8% | 9.9% | Unlock |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.